Veerle Van Dooren

TL;DR: Dual inhibition of Her2 might be a valid approach to treatment of HER2-positive breast cancer in the neoadjuvant setting, and the two anti-HER2 agents given together would be better than single-agent therapy.

TL;DR: The cumulative incidence of any type of cardiac end point increases during the scheduled treatment period of 1 year, but it remains relatively constant thereafter.

TL;DR: Early metabolic assessment using 18F-FDG PET/CT can identify patients with an increased likelihood of pathologic complete response (pCR) to neoadjuvant lapatinib, trastuzumab, or their combination when given with chemotherapy.

TL;DR: The long time intervals required to activate a global phase III trial are highlighted and collaborative research groups, pharmaceutical industry sponsors, and regulatory authorities should enter into dialogue for optimizing local policies to enable faster access of patients to innovative therapies and enhance the efficiency of clinical research.

TL;DR: The incidence of diarrhea was greater with the combination of a taxane and HER2-targeted treatment and decreased once chemotherapy was stopped, and a marked decrease was observed on chemotherapy cessation.